<DOC>
	<DOCNO>NCT03080922</DOCNO>
	<brief_summary>The purpose study evaluate safety efficiency high dose allogeneic mismatch hematopoietic stem cell infusion normal chemotherapy patient relapsed/refractory acute myeloid leukemia（AML） .</brief_summary>
	<brief_title>High Dose Donor Hematopoietic Stem Cell Infusion Relapsed/Refractory AML</brief_title>
	<detailed_description>The relapsed/refractory AML patient receive IA/DA/MA ( I , Idamycin，D，Daunorubicin，M，Mitoxantrone，A，cytosine arabinoside ) chemotherapy follow infusion high dose allogeneic mismatch hematopoietic stem cell . graft-versus-host disease ( GVHD ) prevention conduct transplantation . Cytokine storm , GVHD snd donor graft detect post-transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>Patient relapse and/or refractory AML Estimated life expectancy ≥ 12 week ( accord investigator 's judgment ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Previous treatment investigational gene cell therapy medicine product Any uncontrolled active medical disorder would preclude participation outline</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>hematopoietic stem cell</keyword>
</DOC>